Previous Close | 3.7500 |
Open | 3.7500 |
Bid | 0.9500 |
Ask | 2.1000 |
Strike | 23.00 |
Expire Date | 2024-08-16 |
Day's Range | 3.7500 - 3.7500 |
Contract Range | N/A |
Volume | |
Open Interest | 75 |
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On June 4, 2024, Daniel Spiegelman, Director at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 7,576 shares of the company.
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions. The conditions added to the Universal Plus panel were named in the American College of Medical Genetics and Genomics (ACMG) practice resource for carrier screen